JP2025510490A5 - - Google Patents

Info

Publication number
JP2025510490A5
JP2025510490A5 JP2024547780A JP2024547780A JP2025510490A5 JP 2025510490 A5 JP2025510490 A5 JP 2025510490A5 JP 2024547780 A JP2024547780 A JP 2024547780A JP 2024547780 A JP2024547780 A JP 2024547780A JP 2025510490 A5 JP2025510490 A5 JP 2025510490A5
Authority
JP
Japan
Prior art keywords
antibody
dose
pharmaceutical composition
subject
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024547780A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025510490A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2023/058605 external-priority patent/WO2023194271A1/en
Publication of JP2025510490A publication Critical patent/JP2025510490A/ja
Publication of JP2025510490A5 publication Critical patent/JP2025510490A5/ja
Pending legal-status Critical Current

Links

JP2024547780A 2022-04-04 2023-04-03 抗ｃ５抗体クロバリマブの使用によるギラン・バレー症候群の治療または予防のための投薬量および投与レジメン Pending JP2025510490A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22166586.2 2022-04-04
EP22166586 2022-04-04
PCT/EP2023/058605 WO2023194271A1 (en) 2022-04-04 2023-04-03 Dosage and administration regimen for the treatment or prevention of guillan-barré syndrome by the use of the anti-c5 antibody crovalimab

Publications (2)

Publication Number Publication Date
JP2025510490A JP2025510490A (ja) 2025-04-15
JP2025510490A5 true JP2025510490A5 (https=) 2026-04-03

Family

ID=81327980

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024547780A Pending JP2025510490A (ja) 2022-04-04 2023-04-03 抗ｃ５抗体クロバリマブの使用によるギラン・バレー症候群の治療または予防のための投薬量および投与レジメン

Country Status (11)

Country Link
US (1) US20250236661A1 (https=)
EP (1) EP4504773A1 (https=)
JP (1) JP2025510490A (https=)
KR (1) KR20240168923A (https=)
CN (1) CN118556078A (https=)
AU (1) AU2023248634A1 (https=)
CA (1) CA3251879A1 (https=)
IL (1) IL313962A (https=)
MX (1) MX2024009673A (https=)
TW (1) TW202346339A (https=)
WO (1) WO2023194271A1 (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017011235A2 (pt) 2014-12-19 2018-02-06 Chugai Pharmaceutical Co Ltd anticorpos anti-c5 e métodos de uso
CA3173011A1 (en) * 2020-06-24 2021-12-30 Alexion Pharmaceuticals, Inc. Subcutaneous (sc) administration of anti-c5 antibodies for treatment of complement-associated conditions

Similar Documents

Publication Publication Date Title
JP2023002544A5 (https=)
JP2013543501A5 (https=)
JP2025172841A5 (https=)
JP2025020134A5 (https=)
JP2024174927A5 (https=)
JP2024174962A5 (https=)
CN108601831A (zh) 一种抗pd-1抗体和vegfr抑制剂联合在制备治疗癌症的药物中的用途
JP2021113190A5 (https=)
JP2023551559A5 (https=)
JP2018526460A5 (https=)
JP2022532356A5 (https=)
JP2024069230A5 (https=)
JP2019519584A5 (https=)
IL320562A (en) Cancer treatment methods
JP2005514414A5 (https=)
JP2023545084A5 (https=)
JP2019534251A5 (https=)
JP2025510490A5 (https=)
JP2025500483A5 (https=)
JP2024521105A5 (https=)
JP2024547001A5 (https=)
JP2025511382A5 (https=)
JP2024503379A5 (https=)
JP2005529152A5 (https=)
RU2024129928A (ru) Дозировка и схема введения для лечения или предупреждения синдрома гийена-барре с применением антитела к c5 кровалимаба